OncoPharm

Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.

The latest #oncopharm approval for duvelisib is discussed as well as the similarities and differences to other PI3K inhibitors previously approved.

Discussing the new pseudomonas exotoxin drug (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia (3rd line). Lots of supportive care measures required, surprisingly, for the pseudomonas exotoxin drug.

Celebrating World Marrow Donor Day by recapping the HSCT donation experience of your favorite podcast host.

Delve into the fascinating history of 5-fluorouracil, a pivotal drug in cancer treatment. Discover its unique mechanisms and the range of clinical applications that make it a cornerstone in oncology. The discussion also highlights the importance of dosage and safety management, ensuring effective use while minimizing toxicities. Uncover how this drug has evolved over time and continues to shape cancer therapy today.

The debut of our mailbag (Ask OncoPharm) to give some tips to new oncology pharmacists. Then (13:10) we review the RELEVANCE study of rituximab/lenalidomide in follicular lymphoma.

It's flu shot season, so we're taking a pseudo-systematic review of influenza vaccination in patient receiving chemotherapy. Questions addressed include: How effective is influenza vaccination for cancer patients? What's the optimal timing of vaccination during chemo?

Small cell lung cancer is reviewed, including the milestone advances (chemo + RT, omitting surgery, cis/etoposide) of the past leading up to the latest advance (15:20) - FDA-approval of nivolumab in the 3rd-line setting.

Mogamulizumab-kpkc (MOAs, administration, toxicity) and its FDA-approval is discussed followed by (9:00) updates lenvatinib (a good update) and azithromycin (a bad update) in cancer patients.

Dive into the fascinating journey of rituximab from its dosage origins to its pivotal role in treating B-cell malignancies. The discussion highlights key insights from early clinical trials that shaped current practices. Listeners will also geek out over the latest data on the number needed to treat (NNT) in diffuse large B-cell lymphoma (DLBC). Plus, learn about rituximab's mechanisms, potential side effects, and essential infusion management tips.